Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Next-Generation Antioxidant Inflammation Modulators

Companies Plan to Explore Broad Therapeutic Potential of AIM Class

14-Dec-2011 - Abbott and Reata Pharmaceuticals announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inflammation modulators (AIMs). The agreement is in addition to the partnership between the two companies ...

Reata and Abbott Initiate Global Phase 3 Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes

Pivotal clinical trial will further assess drug candidate's effect on kidney function

20-Jun-2011 - Reata Pharmaceuticals, Inc. and Abbott announced the initiation of a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of bardoxolone methyl in patients with chronic kidney disease (eGFR of 15-29 mL/min/1.73 m2) and type 2 diabetes.The trial, known as BEACON (Bardoxolone methyl ...

Reata and Abbott Announce Positive Phase 2b Study Results for Bardoxolone Methyl

Results Suggest Bardoxolone Methyl May Reduce the Stage of Disease and Improve Measures of Kidney Function in Patients with Chronic Kidney Disease and Type 2 Diabetes

22-Nov-2010 - Reata Pharmaceuticals and Abbott announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other measures of kidney function in ...

Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease

27-Sep-2010 - Abbott and Reata Pharmaceuticals announced that they have entered into a collaboration agreement to develop and commercialize bardoxolone methyl (bardoxolone), which is currently in late Phase 2 trials for the treatment of chronic kidney disease (CKD). Under terms of the agreement, Reata will ...